Author:
Opler M.,Negash S.,Tatsumi K.,Liu C.,Komaroff M.,Capodilupo G.,Hasebe M.,Echevarria B.,Blattner R.,Citrome L.
Reference14 articles.
1. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study;Bugarski-Kirola;Eur. Neuropsychopharmacol.,2014
2. Efficacy and safety of HP-3070, an asenapine transdermal system, in patients with schizophrenia: a phase 3, randomized, placebo-controlled study;Citrome;J. Clin. Psychiatry,2020
3. Psychiatry, the pharmaceutical industry, and the road to better therapeutics;Fibiger;Schizophr. Bull.,2012
4. U.S. department of health, education, and welfare;Guy,1976
5. The positive and negative syndrome scale (PANSS) for schizophrenia;Kay;Schizophr. Bull.,1987